Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Amortization of Deferred Charges (2022 - 2023)

Acro Biomedical has reported Amortization of Deferred Charges over the past 2 years, most recently at $3.1 million for Q2 2023.

  • Quarterly results put Amortization of Deferred Charges at $3.1 million for Q2 2023, down 20.48% from a year ago — trailing twelve months through Jun 2023 was $14.9 million (changed N/A YoY), and the annual figure for FY2022 was $15.7 million, up 105.35%.
  • Amortization of Deferred Charges for Q2 2023 was $3.1 million at Acro Biomedical, down from $3.9 million in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for ACBM hit a ceiling of $3.9 million in Q1 2022 and a floor of $3.1 million in Q2 2023.